VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Asante Gold Corporation (CSE: ASE | GSE: ASG | FRANKFURT:1A9 | U.S.OTC: ASGOF) (“Asante” or the “Company”) is pleased to announce that it has received the second US$100 million advance from Fujairah Holdings LLC (the “Second Advance”), as scheduled under the Gold Forward Agreement (the “Gold Forward Agreement”) described in the Company’s news release of December 19, 2024. Asante has also secured a US$10 million bridge loan facility (the “Bridge ...

Core Insights - Aclaris Therapeutics has initiated a Phase 2 trial for bosakitug, an investigational monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), in patients with moderate-to-severe atopic dermatitis (AD) [1][2] - The trial aims to evaluate the efficacy and safety of bosakitug, with top line results expected in the second half of 2026 [1][2] Company Overview - Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases [7] - The company has a robust R&D engine and a multi-stage portfolio of product candidates [7] Product Details - Bosakitug (ATI-045) is a humanized anti-TSLP monoclonal antibody that blocks TSLP's interaction with its receptor, preventing the release of proinflammatory cytokines [3] - It exhibits high affinity, potency, and a long residence time, potentially allowing for extended dosing intervals [3] Clinical Trial Information - The Phase 2 trial is randomized, double-blind, and placebo-controlled, involving approximately 90 patients [2] - Primary endpoint is the percent change in Eczema Area and Severity Index (EASI) at week 24, with secondary endpoints including various EASI responses and safety assessments [2] Atopic Dermatitis Context - Atopic dermatitis affects approximately 10 million children and 17 million adults in the U.S., with over 200 million affected worldwide [5] - The condition significantly impacts quality of life, with many patients experiencing moderate to severe symptoms [5] TSLP Significance - TSLP is a key cytokine in the Type 2 immune response, driving inflammation in allergic and inflammatory diseases [4] - It activates downstream targets involved in the inflammatory cascade, making it a relevant therapeutic target [4]

Core Insights - Science Applications International Corporation (SAIC) reported a revenue increase of 2% in the first quarter of fiscal year 2026, totaling $1.877 billion compared to $1.847 billion in the same period last year [3][4][7] - The company experienced a decline in operating income, net income, and EBITDA, attributed to contract completions and timing and volume mix in its contract portfolio [4][5][34] - SAIC's backlog at the end of the quarter was approximately $22.3 billion, with net bookings of $2.4 billion, reflecting a book-to-bill ratio of 1.3 [10][11] Financial Performance - Revenues for the quarter increased by $30 million or 2% year-over-year, primarily due to ramp-up in volume in existing and new contracts [4] - Operating income decreased by 8% to $121 million, with an operating margin of 6.4%, down from 7.1% in the prior year [3][4][33] - Net income was $68 million, a decrease of 12% from $77 million in the previous year [3][6] - Adjusted EBITDA was $157 million, representing 8.4% of revenues, down from 9.0% in the prior year [3][5] Cash Flow and Capital Deployment - Cash flows from operating activities increased to $100 million, up from $98 million in the prior year [7][52] - Free cash flow was negative at $(44) million, a significant decline from $13 million in the same quarter last year [3][52] - The company deployed $152 million in capital, including $125 million for share repurchases and $19 million in cash dividends [8] Contract Awards and Backlog - SAIC secured notable contracts, including a $1.8 billion contract with the U.S. Army and a $327 million contract with the Pension Benefit Guaranty Corporation [11][12] - The estimated backlog included approximately $3.3 billion in funded contracts, with a total backlog of $22.3 billion [10][38] Fiscal Year 2026 Guidance - Management reaffirmed fiscal year 2026 guidance, projecting revenues between $7.60 billion and $7.75 billion, with adjusted EBITDA between $715 million and $735 million [14][15]

Core Insights - Pharvaris is advancing its late-stage clinical development of deucrictibant, a novel oral bradykinin B2 receptor antagonist aimed at treating bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][18] - The company plans to present pivotal data readouts for deucrictibant in the next 18 months, highlighting its commitment to addressing unmet medical needs in this area [2][4] Prophylaxis - The ongoing Phase 2 CHAPTER-1 open-label extension study shows that oral deucrictibant maintains a low attack rate for over a year and a half, regardless of baseline attack rates [3] - Participants in the CHAPTER-1 study reported significant improvements in health-related quality of life (HRQoL) and treatment satisfaction, with all participants indicating well-controlled HAE [4] - A pharmacokinetics study demonstrated that the extended-release (XR) formulation of deucrictibant supports once-daily dosing, showing a four-fold higher mean plasma concentration than the therapeutic threshold at 24 hours [5][7] On-Demand Treatment - A post-hoc analysis of the RAPIDe-1 and RAPIDe-2 trials indicated that 95-100% of HAE attacks treated with a single dose of deucrictibant achieved symptom relief without recurrence [9] - The median time to onset of symptom relief was reported as 1.1 hours, with 97.8% of attacks achieving relief within 12 hours [10][11] - Deucrictibant was well tolerated across various attack types, including upper airway attacks, with no treatment-related adverse events reported [11] Expansion Beyond HAE - Pharvaris is exploring a novel biomarker assay for diagnosing bradykinin-mediated angioedema, which could enhance the identification and management of related conditions [12] - The company is also assessing the patient experience and outcome measures for AAE-C1INH, aiming to develop a conceptual model to support clinical assessments [14] - A systematic literature review estimated the prevalence of HAE-C1INH in the EU and UK to be between 0.05-0.33 per 10,000 individuals, indicating a significant need for effective treatments [15]

Core Viewpoint - Patagonia Gold Corp. has successfully completed a US$40 million investment from Black River Mine Inc. for the development of its Calcatreu project in Argentina [1][2]. Financing Details - The investment, referred to as the Calcatreu Financing, involved the issuance of 40 million preferred shares at a price of US$1.00 per share [1]. - Proceeds from the financing will be exclusively used for the development of the Calcatreu project and related expenses [2]. - No finder's fee was paid in connection with the financing, and the preferred shares are non-voting with transfer restrictions [3]. Related Party Transaction - Black River, controlled by Carlos J. Miguens, is considered a related party, owning 43.2% of Patagonia's common shares [4]. - The financing was classified as a "related party transaction" under Multilateral Instrument 61-101, requiring shareholder approval, which was obtained at a special meeting held on May 20, 2025 [4]. Project Overview - The Calcatreu project is located in Rio Negro province, approximately 85 kilometers south of Ing Jacobacci [5]. - Patagonia acquired the project from Pan American Silver in 2018 and has since been focused on obtaining necessary permits for development [6]. - The project has an estimated 746,000 contained AuEq ounces in measured and indicated resources and 390,000 contained AuEq ounces in inferred resources [7]. Technical Information - The scientific and technical information in the news release has been reviewed and approved by Donald J. Birak, a qualified person as defined by National Instrument 43-101 [8]. - Additional details about the project and mineral resources are available in the technical report dated December 31, 2018 [9]. Company Background - Patagonia Gold Corp. is a publicly traded mining company focused on gold and silver projects in South America, primarily the Calcatreu project and the Cap-Oeste underground project [10][11].

Core Viewpoint - Codere Online has filed its annual report on form 20-F for the year ended December 31, 2024, with the SEC, indicating a step towards compliance with Nasdaq Listing Rule 5250(c)(1) [1][2]. Company Overview - Codere Online is a leading online gaming operator in Spain and Latin America, launched in 2014 as part of the Codere Group, which is known for its casino operations [5]. - The company offers online sports betting and casino services through its website and mobile applications, operating in key markets including Spain, Mexico, Colombia, Panama, and Argentina [5]. Compliance and Regulatory Updates - By filing the 2024 20-F, the company believes it has regained compliance with Nasdaq Listing Rule 5250(c)(1), which may eliminate the need for a hearing regarding a delisting determination [2]. - The company is awaiting formal confirmation from Nasdaq regarding its compliance status [2]. Environmental Considerations - To reduce environmental impact, the company encourages shareholders to read the annual report in digital format, although hard copies are available upon request [4].

Castellum, Inc. to Participate in the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow” Castellum, Inc. (NYSE-American: CTM), announces that its Chief Executive Officer, Glen Ives, has been invited to present at the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow,” presented by Maxim Group LLC, on Tuesday, June 3rd – Thursday, June 5th at 9:00 a.m. EDT - www.castellumus.com VIENNA, Va., June 02, 2025 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-America ...

Core Insights - Brazil Potash Corp. has made significant progress in governance, commercial partnerships, construction, and financial initiatives for the Autazes Potash Project, which is crucial for Brazil's agricultural security [1][2] Group 1: Achievements and Progress - The company has established a $75 million equity line of credit with Alumni Capital, enhancing its capital access for project advancement [5] - Brazil Potash signed a Memorandum of Understanding (MOU) with Keytrade AG for potential offtake of up to one million tons per year, moving towards approximately 1.5 million tons of committed production [6] - The company has strengthened government relations through strategic meetings with key stakeholders, including the Amazonas State Governor and the Mura Indigenous Council [6] Group 2: Leadership and Governance - Mayo Schmidt was appointed as Executive Chairman in January 2025, bringing experience from Nutrien, the world's largest fertilizer company [6] - Christian Joerg was added to the Board of Directors, contributing three decades of experience in agricultural commodities and international trade finance [6] - The Advisory Board was expanded with Marcelo Lessa, a former IFC/World Bank executive with extensive project financing expertise [6] Group 3: Construction and Operational Advancements - The company received approval to begin fauna rescue and vegetation suppression activities, enabling subsequent shaft sinking operations [6] - Site preparation work at the future port terminal has been completed, marking a critical infrastructure milestone [6] - Water extraction installation licenses have been converted to full operational permits, securing water supply for construction and operations [6] Group 4: Market Context and Future Outlook - Brazil Potash aims to produce up to 2.4 million tons of potash annually, potentially supplying approximately 20% of Brazil's current potash demand [7] - The project is expected to reduce Brazil's reliance on potash imports while mitigating approximately 1.4 million tons per year of greenhouse gas emissions [7]

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor typesThe co-development and co-commercialization collaboration with a 50/50 profit/loss split will leverage both partners’ expertise, resources and global footprint to accelerate BNT327’s path towards potential regulatory approvals and market launchesBioNTech and Bristol Myers ...

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continuesThe safety profile of atacicept was favorable, a ...